- Design
- Systematic review and random-effects dose-response meta-analysis of observational and cohort studies, with GRADE certainty assessment
- Population
- Eleven studies published 1990-2024 reporting baseline vitamin D levels and chronic kidney disease progression outcomes
- Primary outcome
- Pooled odds of chronic kidney disease progression by vitamin D status, and per 10 ng/mL of 25-hydroxyvitamin D
- Effect
- OR 1.33 (95% CI 1.06-1.67, p=0.019), I-squared 98.2%; dose-response OR 1.18 (1.09-1.25) per 10 ng/mL lower; GRADE certainty very low
Vitamin D deficiency is near-universal in chronic kidney disease and gets supplemented on the assumption that correcting it helps. This dose-response meta-analysis of eleven observational and cohort studies, published between 1990 and 2024, asked what the association with progression actually is.
Vitamin D deficiency was associated with 33% higher odds of progression (OR 1.33, 95% CI 1.06-1.67, p=0.019), and the dose-response analysis of ten studies suggested 18% higher odds per 10 ng/mL lower 25-hydroxyvitamin D (OR 1.18, 1.09-1.25). Studies with five or more years of follow-up showed a stronger association (OR 2.07, 1.29-3.14).
Then the caveats, which the authors state plainly and which are larger than the finding. Heterogeneity was 98.2% - the studies do not agree with each other, and a pooled estimate across studies that disagree that completely is an average of incompatible results rather than a summary of a consistent one. GRADE certainty was rated very low for the overall association and low for the dose-response. The dose-response used reconstructed category-level exposure values rather than individual data.
The authors' own conclusion is the right one to carry: this does not establish that screening for or supplementing vitamin D prevents kidney function decline. Low vitamin D is a marker of being unwell, being indoors, being frail and eating badly, all of which independently predict progression.
So continue to manage vitamin D in chronic kidney disease for the reasons that already justify it - bone health and secondary hyperparathyroidism, per existing guidance - and do not add renal protection to the list of things you tell a patient it will do. In India, where vitamin D deficiency is extremely common and supplements are sold freely, resisting that extra claim matters more than usual.
- Do not offer vitamin D supplementation as a way to slow kidney function decline
- Continue existing indications: bone health and secondary hyperparathyroidism management
- Treat 98.2% heterogeneity as a reason to distrust the pooled number, not a technicality
- Remember low vitamin D marks poor health generally - it is a confounded exposure
- The evidence that would settle this is a randomised trial, and it has not been done
The statistics, in plain English
An I-squared of 98.2% means almost all the variation between study results comes from real differences between the studies rather than chance - pooling them produces a number, but not a trustworthy one. GRADE 'very low certainty' is the lowest rating available and means the true effect is likely to be substantially different from the estimate. The stronger association in long-follow-up studies (OR 2.07) is a subgroup finding from a handful of studies and is at least as likely to reflect who those studies enrolled as any biological gradient. An odds ratio from observational data cannot separate 'low vitamin D worsens kidneys' from 'worse kidneys and worse health lower vitamin D'.
Read the rest in the app
You have read your two free briefings this month. The app carries all 27 specialties, every morning, free — and this finding is waiting in it.
Scan to keep reading on your phone. No account needed to start.
Tomorrow morning, before your first patient
One edition a day for nephrology, written by the desk, every claim tied to its paper. Six minutes.
Get the app — free